Relpax All Financial Data in US $ (mln)

Word Search (Top 10 - by date)

Immunocore appoints Dr Eliot Forster as Chief Executive Officer
Immunocore (January 12, 2015)
Pfizer (May 05, 2014)

Displaying 10 out of a possible 82 unique stories.
Results Sorted By date
Display All Stories

EvaluatePharma® - the premier source for pharma and biotech analysis.

Expert integration of financial and product data across historic and forecast timeframes (1986 to 2016) delivers a vast array of analytics by product, company, therapy area, EphMRA ATC code, technology, patent status (expiry date/ number), deals (upfront/ milestones), license revenues (royalties/ co-promotion) and much more.

Product Name Information

Product: Relpax
Generic Name:   eletriptan hydrobromide
Therapeutic Subcategory:     Anti-migraine preparations

Product Sales Summary 2010/11

Annual Sales WW - Sales Growth per Year (%)
Rank1 Generic Name Therapeutic Subcategory 2010 2011 2011
Relpax2 323 341 +6%
Note: Shaded Cells3

Clinical Trial Coverage: No. of Trials involving Product

Trial Count
Relpax4 21


Evaluate provides market intelligence and analysis for the pharma, biotech and medtech industries.

Explore Evaluate


EvaluatePharma® now includes Partnering Opportunities - products available for licensing.

Partnering Opportunities in EvaluatePharma® are sourced from the rights holders - all entries are verified by the team of Analysts at EvaluatePharma - and presented in their commercial context.

Register to submit your Partnering Opportunities or to see your own and other Partnering Opportunities in their commercial context with the unique industry-wide analysis in EvaluatePharma®.

Take a full subscription to see all products available for license, including updated contact details for the out-licensing entity.

Register to access more FREE content:

  • 2011 Product Sales analysis
  • Download analysis into Excel
  • Search 2 yrs of company press releases

Research Codes Synonyms

Product: Relpax

Register for Free Analysis

Register to access more free insights and analysis from Evaluate.

Register Now